Wednesday, September 16, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· June 2, 2026

Nanobiotix Provides First Quarter 2026 Operational and Financial Update

View original at finance.yahoo.com
Nanobiotix Provides First Quarter 2026 Operational and Financial Update Nanobiotix S.A…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Complete response rate of 57.1% (4/7 patients) observed in CONVERGE Part 1 cohort, reported at ESTRO 2026

    60% confidence

  • With standard of care (cCRT ± durvalumab), depth of response in Stage 3 Inoperable NSCLC is limited with very low rates of complete response below 5%

    60% confidence

  • Nanoprimer pre-treatment followed by LNP-DNA administration showed increased systemic bioavailability, reduced hepatic toxicity, and reduced cGAS-STING related inflammation compared to LNP-DNA alone in preclinical data

    60% confidence

  • Absence of progressive disease and deepening response over time in CONVERGE patients suggests potential for long-term durability of JNJ-1900 treatment

    60% confidence

  • ORR of 71.4% (5/7 patients) observed at earlier time point in same CONVERGE cohort and reported at ELCC 2026

    60% confidence

  • Early results suggest intratumoral/intranodal injection of JNJ-1900 is feasible and can be performed safely in patients with stage III unresectable NSCLC

    60% confidence

  • Overall response rate of 85.7% (6/7 patients) observed in CONVERGE Part 1 cohort following full treatment regimen of cCRT, JNJ-1900, and durvalumab consolidation, reported at ESTRO 2026

    60% confidence

  • CONVERGE treatment procedure demonstrated an acceptable safety profile without serious treatment-emergent adverse events

    60% confidence

  • Nanobiotix continues to advance with focus, discipline, and ambition to unlock the full potential of physics-based nanotherapeutics; Q1 2026 strengthened the foundation via JNJ-1900 advancement, Nanoprimer progress, and reinforced financial position

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI's 'Show-Me' Reckoning: Earnings Divergence, Executive Exodus, and Regulatory Tightening
Investors are shifting from rewarding AI narratives to demanding tangible results, evidenced by Adobe's weak guidance despite user-growth emphasis, Palantir's stock decline even after winning the Army's TITAN contract, and UiPath's contrasting guidance raise. Simultaneously, high-profile safety-driven departures from Anthropic and Google, plus new regulatory actions (California's under-16 social media ban, Anthropic's misuse-blocking disclosures), signal mounting scrutiny of AI's societal and financial risk profile even as fintech-adjacent funding (Socure) continues.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,288 source documents archived
Query this data → isubstrate.com